NDRI Elects Paul M. Lieberman, Ph.D., to Board of Directors
Retrieved on:
Wednesday, December 1, 2021
Oncology, Health, Hospitals, Research, Science, Pharmaceutical, Biotechnology, Gene expression, Tissue, National, Chemical biology, Cell, Wistar Institute, Public sector banks in India, AAAS, TSS, Publication, OPOS, University of California, San Francisco, Hospital, Cancer, Virus, University, National Cancer Institute, Shepherd University, Institute, Johns Hopkins School of Medicine, Cornell University, Center, Research, Hilary Koprowski, National Disease Research Interchange, Eye, NDRI, Board, Organization, Translational medicine, Epstein–Barr virus, University of Michigan Rogel Cancer Center, Biomedical Research, Multimedia, Infection, Doctor of Philosophy, Association, EBV, Pharmaceutical industry, Management
Philadelphia-based National Disease Research Interchange (NDRI) announces the election of Paul M. Lieberman, Ph.D., to its Board.
Key Points:
- Philadelphia-based National Disease Research Interchange (NDRI) announces the election of Paul M. Lieberman, Ph.D., to its Board.
- (Photo: Business Wire)
Lieberman is a molecular virologist and an expert in gene expression and regulation at Wistars Cancer Center. - Mary J.C. Hendrix, Ph.D., Chair of the NDRI Board and President of Shepherd University, shared, We are thrilled to welcome Dr. Lieberman to the NDRI Board of Directors.
- The National Disease Research Interchange (NDRI) is the nations leading source of human tissues, cells and organs for scientific research.